Intradermal influenza vaccine and new devices

A promising chance for vaccine improvement

Filippo Ansaldi, Paolo Durando, Giancarlo Icardi

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Introduction: The main public health strategy for reducing the influenza burden is annual vaccination. However, because the immune response in the elderly and frail subjects is known to be less vigorous than in younger adults, novel strategies have been explored in the last decade to augment immune response after immunization. These have included an increased dosage, multiple dose vaccinations, use of vaccine adjuvants and more efficient routes of vaccine delivery. Areas covered: This review discusses recent advances in intradermally administered influenza vaccines with particular attention to immunogenicity and safety data from clinical trials performed using appropriate injection systems which, combining consistent injection depth and volume, safety, simplicity and ease-of-use, allowed large scale evaluation. Expert opinion: Substantial experience has been accumulated with Intanza 9 and Intanza 15 μg/IDflu 15 μg, administered using BD's Soluvia device, and are the first intradermal trivalent inactivated split-virion influenza vaccines to be licensed for use in 18-59 year adults and in elderly people, respectively. Clinical data showed that they are safe and immunogenic and can offer significant advantages in terms of higher acceptability, higher immunogenicity in the elderly and dose-sparing in adults younger than 60 years when compared with intramuscularly administered vaccine.

Original languageEnglish
Pages (from-to)415-427
Number of pages13
JournalExpert Opinion on Biological Therapy
Volume11
Issue number3
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Influenza Vaccines
Vaccines
Equipment and Supplies
Young Adult
Vaccination
Immunization
Safety
Frail Elderly
Injections
Expert Testimony
Public health
Virion
Human Influenza
Public Health
Clinical Trials

Keywords

  • device
  • immunogenicity
  • influenza vaccine
  • intradermal
  • safety

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Intradermal influenza vaccine and new devices : A promising chance for vaccine improvement. / Ansaldi, Filippo; Durando, Paolo; Icardi, Giancarlo.

In: Expert Opinion on Biological Therapy, Vol. 11, No. 3, 03.2011, p. 415-427.

Research output: Contribution to journalArticle

Ansaldi, Filippo ; Durando, Paolo ; Icardi, Giancarlo. / Intradermal influenza vaccine and new devices : A promising chance for vaccine improvement. In: Expert Opinion on Biological Therapy. 2011 ; Vol. 11, No. 3. pp. 415-427.
@article{8ae5fc4c1d3b4c88a4047fdd35e033ee,
title = "Intradermal influenza vaccine and new devices: A promising chance for vaccine improvement",
abstract = "Introduction: The main public health strategy for reducing the influenza burden is annual vaccination. However, because the immune response in the elderly and frail subjects is known to be less vigorous than in younger adults, novel strategies have been explored in the last decade to augment immune response after immunization. These have included an increased dosage, multiple dose vaccinations, use of vaccine adjuvants and more efficient routes of vaccine delivery. Areas covered: This review discusses recent advances in intradermally administered influenza vaccines with particular attention to immunogenicity and safety data from clinical trials performed using appropriate injection systems which, combining consistent injection depth and volume, safety, simplicity and ease-of-use, allowed large scale evaluation. Expert opinion: Substantial experience has been accumulated with Intanza 9 and Intanza 15 μg/IDflu 15 μg, administered using BD's Soluvia™ device, and are the first intradermal trivalent inactivated split-virion influenza vaccines to be licensed for use in 18-59 year adults and in elderly people, respectively. Clinical data showed that they are safe and immunogenic and can offer significant advantages in terms of higher acceptability, higher immunogenicity in the elderly and dose-sparing in adults younger than 60 years when compared with intramuscularly administered vaccine.",
keywords = "device, immunogenicity, influenza vaccine, intradermal, safety",
author = "Filippo Ansaldi and Paolo Durando and Giancarlo Icardi",
year = "2011",
month = "3",
doi = "10.1517/14712598.2011.557658",
language = "English",
volume = "11",
pages = "415--427",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Intradermal influenza vaccine and new devices

T2 - A promising chance for vaccine improvement

AU - Ansaldi, Filippo

AU - Durando, Paolo

AU - Icardi, Giancarlo

PY - 2011/3

Y1 - 2011/3

N2 - Introduction: The main public health strategy for reducing the influenza burden is annual vaccination. However, because the immune response in the elderly and frail subjects is known to be less vigorous than in younger adults, novel strategies have been explored in the last decade to augment immune response after immunization. These have included an increased dosage, multiple dose vaccinations, use of vaccine adjuvants and more efficient routes of vaccine delivery. Areas covered: This review discusses recent advances in intradermally administered influenza vaccines with particular attention to immunogenicity and safety data from clinical trials performed using appropriate injection systems which, combining consistent injection depth and volume, safety, simplicity and ease-of-use, allowed large scale evaluation. Expert opinion: Substantial experience has been accumulated with Intanza 9 and Intanza 15 μg/IDflu 15 μg, administered using BD's Soluvia™ device, and are the first intradermal trivalent inactivated split-virion influenza vaccines to be licensed for use in 18-59 year adults and in elderly people, respectively. Clinical data showed that they are safe and immunogenic and can offer significant advantages in terms of higher acceptability, higher immunogenicity in the elderly and dose-sparing in adults younger than 60 years when compared with intramuscularly administered vaccine.

AB - Introduction: The main public health strategy for reducing the influenza burden is annual vaccination. However, because the immune response in the elderly and frail subjects is known to be less vigorous than in younger adults, novel strategies have been explored in the last decade to augment immune response after immunization. These have included an increased dosage, multiple dose vaccinations, use of vaccine adjuvants and more efficient routes of vaccine delivery. Areas covered: This review discusses recent advances in intradermally administered influenza vaccines with particular attention to immunogenicity and safety data from clinical trials performed using appropriate injection systems which, combining consistent injection depth and volume, safety, simplicity and ease-of-use, allowed large scale evaluation. Expert opinion: Substantial experience has been accumulated with Intanza 9 and Intanza 15 μg/IDflu 15 μg, administered using BD's Soluvia™ device, and are the first intradermal trivalent inactivated split-virion influenza vaccines to be licensed for use in 18-59 year adults and in elderly people, respectively. Clinical data showed that they are safe and immunogenic and can offer significant advantages in terms of higher acceptability, higher immunogenicity in the elderly and dose-sparing in adults younger than 60 years when compared with intramuscularly administered vaccine.

KW - device

KW - immunogenicity

KW - influenza vaccine

KW - intradermal

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=79851480211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79851480211&partnerID=8YFLogxK

U2 - 10.1517/14712598.2011.557658

DO - 10.1517/14712598.2011.557658

M3 - Article

VL - 11

SP - 415

EP - 427

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 3

ER -